Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Radiopharm Theranostics Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2025
FY2025
Revenue
0.29
0.3
3.63
Cost of revenue
3.59
Gross profit
0.29
0.3
0.04
Research and development
22.6
23.1
27.5
Operating income
-34.5
-47.2
-38.2
Interest expense
0.09
0.64
0.07
Pre-tax income
-34.6
-47.9
-38.2
Income tax
0.04
0.1
0.1
Net income
-34.6
-47.9
-38.3
EPS, basic
-11.32
-12.41
-1.76
EPS, diluted
-11.32
-12.41
-1.76
Balance sheet
FY2023
FY2025
FY2025
Cash and equivalents
11.7
18.6
29.1
Receivables
4.47
0.99
10.4
Total current assets
22.8
39.9
Property, plant and equipment
0.06
0.05
Intangible assets
58.5
49.1
46.6
Total assets
72
86.5
Accounts payable
5.12
10.9
9.34
Total current liabilities
17.6
14.9
Total liabilities
44.7
43.6
Minority interests
-0.77
-1.92
Total equity
45.6
27.4
42.9
Total liabilities and equity
72
86.5
Cash flow statement
FY2023
FY2025
FY2025
Net income
-34.6
-47.9
-38.3
Cash from operations
-23.2
-23
-36.6
Capital expenditures
-0.05
Cash from investing
-1.53
-0.32
1.77
Debt issued
7.37
Stock issued
10.1
29.6
54
Cash from financing
9.22
30.2
45.4
Exchange rate effect
0.23
-0.03
-0.01
Free cash flow
-23.2
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.52 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
1.1%
Gross profit / revenue.
Operating margin
-1,051.0%
Operating income / revenue.
Pre-tax margin
-1,052.0%
Pre-tax income / revenue.
Net margin
-1,055.0%
Net income / revenue.
Operating cash flow margin
-1,009.0%
Cash from operations / revenue.
Return on assets (ROA)
-48.4%
Net income / average total assets.
R&D / revenue
757.3%
Research and development expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
1,114.0%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
-86.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
20.1%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.67x
Current assets / current liabilities.
Quick ratio
2.65x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.95x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
50.4%
Total liabilities / total assets.
Interest coverage
-585x
Operating income / interest expense.
Working capital
$24.9M
Current assets - current liabilities.
Goodwill and intangibles / assets
53.9%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.05x
Revenue / average total assets.
Fixed asset turnover
63.6x
Revenue / average property, plant and equipment.
Receivables turnover
0.64x
Revenue / average receivables.
Days sales outstanding
572 days
365 x average receivables / revenue.
Days payables
1,026 days
365 x average accounts payable / cost of revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.76
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$1.76
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$21.9M
Share price x shares outstanding.
Enterprise value
-$7.3M
Market cap + total debt - cash - short-term investments.
P/S
6.01x
Market cap / revenue.
Earnings yield
-175.5%
Net income / market cap (the inverse of P/E).
What was Radiopharm Theranostics Ltd's revenue in fiscal 2025?
Radiopharm Theranostics Ltd reported revenue of $3.6M for fiscal 2025, 1,114.3% higher than the year before.
Was Radiopharm Theranostics Ltd profitable in fiscal 2025?
No. It reported a net loss of $38.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.